Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Transitional Cell
  • Paclitaxel
  • Taxoids
  • Urologic Neoplasms

abstract

  • Docetaxel is an active single agent in previously treated patients with TCC of the urothelial tract. Therapy was well tolerated in this patient population but myelosuppression was frequent. Further study in previously untreated patients, both alone and in combination, is warranted.

publication date

  • May 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9164195

Additional Document Info

start page

  • 1853

end page

  • 7

volume

  • 15

number

  • 5